Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 10/20 | 1.00 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212658 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL6013928 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1PDPK1CHRNA7 | |
| SCHEMBL6352647 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1ABCB11ALDH1A1CHRNA7 | |
| SCHEMBL7789562 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL213150 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL3249718 | 0.88 | PTGS2 (0.95) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL8635509 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL3243184 | 0.88 | PTGS2 (0.82) | PTGS2PTGS1ABCB11ALDH1A1 | |
| SCHEMBL6339195 | 0.88 | PTGS2 (0.90) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 | |
| SCHEMBL215341 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1PDPK1ABCB11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. | 2019-02-07 | — | — | US | disclosed |
| EP-3413889-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | Cocoon Biotech Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139684-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS SILK FIBROIN AND A GELLING AGENT AND USES THEREOF | COCOON BIOTECH INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-RE44048-E1 | 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder | G.D. SEARLE LLC (US) | 2013-03-05 | — | — | US | disclosed |
| CN-101242875-A | Ophthalmic composition containing mucoadhesive polysaccharides capable of promoting corneal re-epithelialization | OPOCRIN SPA (IT) | 2008-08-13 | — | — | CN | disclosed |
| CN-100379727-C | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-1268614-C | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2006-08-09 | — | — | CN | disclosed |
| CN-1699347-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | SEARLE & CO (US) | 2005-11-23 | — | — | CN | disclosed |
| US-6951949-B2 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| CN-1339020-A | Process for producing vitamin | DCV INC (US) | 2002-03-06 | — | — | CN | disclosed |
| CN-1280125-A | Substituted pyrazolyl benzene sulfone amides compounds for curing inflammation | SEARLE & CO (US) | 2001-01-17 | — | — | CN | disclosed |
| CN-1280126-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 2001-01-17 | — | — | CN | disclosed |
| US-6156781-A | Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation | G. D. SEARLE & CO. (US) | 2000-12-05 | — | — | US | disclosed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | disclosed |
| EP-0854723-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011704-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR USE IN VETERINARY THERAPIES AS ANTIINFLAMMATORY AGENTS | G.D. SEARLE & CO. (US) | 1997-04-03 | — | — | WO | disclosed |
| CN-1141630-A | Substituted pyrazolyl benzenesulfonamides for treating inflammation | SEARLE & CO (US) | 1997-01-29 | — | — | CN | disclosed |
| EP-0731795-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | disclosed |
| WO-1995015316-A1 | SUBSTITUTED PYRAZOLYL BENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATION | G. D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038756-A1 | COMPOSITIONS INCLUDING BENZENESULFONAMIDE-CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, SILK FIBROIN, AND A GELLING AGENT AND USES THEREOF | MB, PTGES, PTGS1 | PTGS2 12/4885PTGS1 3/4885PDPK1 4020/4885 |
| US-20050131050-A1 | Substituted pyrazolyl benzenesulfonamides for the treatment of inflamation | IRAK2, IRAK4, IRAK3 | PTGS2 230/4885PTGS1 377/4885PDPK1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.